Skip to main content
. 2022 Jul 22;62(4):605–611. doi: 10.2169/internalmedicine.9815-22

Figure 4.

Figure 4.

Clinical course and hemostatic parameters after rituximab treatment. Rituximab monotherapy decreased the serum levels of IgA, in parallel with an increase in plasma levels of VWF:RCo and normalization of APTT. IgA: immunoglobulin A, pdFWF/FVIII: plasma-derived von Willebrand factor/factor VIII, VWF/RCo: von Willebrand factor ristocetin cofactor activity